Ann: Imugene to present at 2024 Cholangiocarcinoma Conference, page-104

“The abstract, titled ‘CF33-hNIS, a novel oncolytic virus for the treatment ofcholangiocarcinoma and biliary tract malignancies,’ concludes that CF33-hNISmonotherapy may be an effective and safe treatment option for GI malignancies”

This “conclusion” will hopefully be supported by some solid new data. Ideally something along the lines of an improvement to the cohort response rates (listed ASCO-GI Symposium in Jan) showing complete response across the board.

If Vaxinia is showing that it’s significant reducing malignancies (albeit in a small cohort at Ph1) the this can only get add impetus to the FDA fast track process and get IMU closer to the aim of entry into the Accelerated Approvals Program (link below to FDA site regarding the program).

https://www.fda.gov/drugs/nda-and-bla-approvals/accelerated-approval-program

Fingers crossed.

k